The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors
Published version of a preprint
Abstract
Purpose: NC-6004, a novel cisplatin nanoparticle developed using micellar technology exhibits sustained release of cisplatin and selective distribution to tumors. Preclinical data demonstrated a favorable tolerability profile and preserved or improved antitumor activity compared with cisplatin across animal models. We evaluated the safety and tolerability of NC-6004 and gemcitabine using a Bayesian continual reassessment model (N-CRM) to determine the optimal dose. Experimental Design: Patients with advanced solid tumors received NC-6004 at 60 to 180 mg/m2 on day 1 and gemcitabine at 1,250 mg/m2 on days 1 and 8 every 3 weeks. Dose escalation of NC-6004 began with a single patient run-in until a dose-limiting toxicity occurred at 180 mg/m2. Cohorts of four patients were enrolled at doses predicted by the N-CRM. The maximum tolerated dose (MTD) was defined as having the greatest probability of target toxicity <25%. Quality of life was assessed using EORTC-QLQ-C30. Results: Among 22 patients, the most common grade III/IV hematologic adverse events were leukopenia (68%) and thrombocytopenia (59%). Of 20 pretreated patients evaluable for response, half were previously exposed to a platinum agent. The MTD was 135 mg/m2. Nine patients were treated at the MTD with median treatment duration of 15 weeks (range, 3–50). Tumor shrinkage occurred in 11 (55%), partial responses in 3 (15%), and stable disease in 14 (70%). Most patients reported stable or improved EORTC QLQ-C30 scores. Conclusions: Greater cisplatin equivalent doses were achieved with no clinically significant neuro-, oto-, or nephrotoxicity. These data demonstrate tolerability and promising activity of NC-6004 in combination with gemcitabine. Clin Cancer Res; 24(1); 43–51. ©2017 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A Phase Ib/II trial of NC-6004 with gemcitabine was conducted in patients with advanced solid tumors to evaluate the safety and tolerability (ClinicalTrials.gov: NCT02240238) [309]. NC-6004 was administered to patients at 60 mg/m2 to 180 mg/m2 (on day 1) with gemcitabine (1,250 mg/m2, on days 1 and 8) every 3 weeks. A dose of 135 mg/m2 of NC-6004 was determined as the MTD and common hematologic”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [309]
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429 · cited 1×
“The small size of NC-6004 micelles provide an advantage over other formulations of doxorubicin or paclitaxel using albuminor liposomal-based nanovehicleswhich are 90 and 130 nm, respectively, and enables greater accumulation and penetration of poorly permeable organs such as the pancreas (16).”
BackgroundPolyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282 · cited 1×
“Polyethylene glycol, a major component of the nanoparticle has been utilized inmanyother drug delivery systems and is approved globally with no known associated toxicities (29).”
BackgroundEnhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841 · cited 1×
“Nanoparticles capitalize on the EPR effect by exploiting abnormalities of tumor vasculature, namely hypervascularization, fenestrated vasculature, and retaining intratumorally via a lack of a tumor lymphatic drainage system (24).”
BackgroundForastiere, A. A., Metch, B., Schuller, D. E., Ensley, J. F., Hutchins, L. F., Triozzi, P., Kish, J. A., McClure, S., VonFeldt, E., & Williamson, S. K. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1245 · Cited by 752 · cited 6×
“Increased GGT 4 (44) 1 (11) 13 (59) 1 (5)”
InfluentialNovel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 710
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604 · cited 1×
“Continuous use of cisplatin is associated with neurotoxicity, myelotoxicity, and gastrointestinal toxicity including nausea and vomiting (5, 6).”
BackgroundRoila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., Clark-Snow, R. A., Dupuis, L. L., Einhorn, L. H., Feyer, P., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw270 · Cited by 574
Critical aspects of the Bayesian approach to phase I cancer trials
Neuenschwander, B., Branson, M., & Gsponer, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3230 · Cited by 439 · cited 1×
“Hyperglycemia 2 (22) 1 (11) 8 (36) 2 (9)”
Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430 · cited 1×
“Preclinical data also demonstrate that NC-6004 has a favorable tolerability profile (nephrotoxicity and neurotoxicity) and preserved or improved antitumor activity compared with cisplatin (19).”
Background
Research works printed but not linked: 4
- 2011, Platinol® (cisplatin for injection, USP) [package insert]
- Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387
- 2015, NanoCarrier Investigator Brochure Edition 9.0
- Reitsma, 2015, We can improve trials using adaptive designs, Applied Clinical Trials, 35
Cited by
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
“Subbiah et al.(34) developed a polymeric formulation of NC-6004 consisting of PEG-b-poly(a,b-aspartic acid) and cisplatin, which are being investigated under a phase III trial for the treatment of advanced metastatic pancreatic cancer.”
BackgroundHwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
“showed modest efficacy in phase II study [309].”
BackgroundMetallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
Su, S., & M. Kang, P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090837 · Cited by 259
Metadata
- Authors
- Subbiah, V., Grilley-Olson, J. E., Combest, A. J., Sharma, N., Tran, R. H., Bobe, I., Osada, A., Takahashi, K., Balkissoon, J., Camp, A., Masada, A., Reitsma, D. J., & Bazhenova, L. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- 2UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
- University of North Carolina at Chapel Hill (US)
- University Hospitals of Cleveland (US)
- Pharmaceutical Product Development (United States) (US)
- NanoCarrier (Japan) (JP)
- University of California San Diego (US)
- Corresponding author
- Subbiah, Vivek
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2018-01-01
- Volume
- 24
- Issue
- 1
- Pages
- 43-51
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2764334703
- Cited by
- 118
- References
- 28
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 11 · 2023: 7 · 2022: 25 · 2021: 16 · 2020: 12 · 2019: 13 · 2018: 6
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas MD Anderson Cancer Center NIH (CA016672)
- NCATS (UL1 TR000371)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- gemcitabine, combination chemotherapy, advanced solid tumors, maximum tolerated dose, dose-limiting toxicity, hematologic toxicity, leukopenia, thrombocytopenia, quality of life, platinum rechallenge, anticancer activity
- MeSH terms
- Gemcitabine, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Organoplatinum Compounds, Polyglutamic Acid, Quality of Life, Treatment Outcome, Drug Monitoring, Drug Resistance, Neoplasm, Retreatment, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1114
- The paper
- Subbiah, V., Grilley-Olson, J. E., Combest, A. J., Sharma, N., Tran, R. H., Bobe, I., Osada, A., Takahashi, K., Balkissoon, J., Camp, A., Masada, A., Reitsma, D. J., & Bazhenova, L. A. (2018). Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.